Combined Rituximab + Omalizumab Promising for Refractory BP Combined Rituximab + Omalizumab Promising for Refractory BP

Bullous pemphigoid has high morbidity and mortality, especially in people with comorbidities common to older adults, yet no Food and Drug Administration –approved therapies for BP exist.MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Dermatology Source Type: news